AC
SYRE icon

Armistice Capital’s Spyre Therapeutics SYRE Stock Holding History

Armistice Capital’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.2M Buy
137,588
+16,657
+14% +$1.22M 0.15% 93
2026
Q1 		$6.1M Sell
120,931
-75,495
-38% -$2.85M 0.11% 116
2025
Q4 		$6.43M Buy
196,426
+40,426
+26% +$1.06M 0.08% 120
2025
Q3 		$2.61M Sell
156,000
-16,000
-9% -$261K 0.04% 140
2025
Q2 		$2.57M Sell
172,000
-28,000
-14% -$414K 0.04% 125
2025
Q1 		$3.23M Hold
200,000
– – 0.05% 133
2024
Q4 		$4.66M Buy
200,000
+64,000
+47% +$1.88M 0.06% 124
2024
Q3 		$4M Hold
136,000
– – 0.06% 132
2024
Q2 		$3.2M Buy
+136,000
New +$4.59M 0.04% 132

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Armistice Capital's SYRE Position: Q2 2026 in Review

Armistice Capital increased its Spyre Therapeutics (SYRE) stake by 14% in Q2 2026, buying an estimated $1.22M and bringing the position to 137,588 shares worth $12.2M. The position accounts for 0.15% of the portfolio, ranked #93.

Armistice Capital first reported a position in SYRE in Q2 2024 and has held it in 9 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Armistice Capital held 137,588 shares of Spyre Therapeutics worth $12.2M as of Q2 2026.
  • Armistice Capital bought 16,657 Spyre Therapeutics shares in Q2 2026, an estimated $1.22M.
  • Spyre Therapeutics made up 0.15% of Armistice Capital's portfolio in Q2 2026, its #93 holding.
  • Armistice Capital first reported a position in Spyre Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.